الفهرس 
Anemia of chronic Kidney DiseaseOnly 14 pages are availabe for public view
 |  | from | 117 |  |  |
| | | from | 117 | | |
Abstract
Background: Hemodialysis represents the main mode for treatment of chronic kidney disease stage 5 (CKD5). Anemia is one of disorders may develop as a consequence of the loss of renal function.
Aim of the Work: To Study the relationship between fibroblast growth factor-23 and Anemia in diabetic patients on regular hemodialysis.
Methodology: This was an analytical case control study on 90 patients who have end stage kidney disease on regular hemodialysis during 2015, In Al-Agouza Hospital; Patients were divided into 2 groups: group 1: 45 patient diabetic, ESKD on regular hemodialysis, and level of hemoglobin less than 11 gm\dl. group 2: 45 patient not diabetic, ESKD on regular hemodialysis, and level of hemoglobin less than 11gm\dl.
Results: This is an analytical case control study on 90 patients which have end stage kidney disease on regular hemodialysis, during 2015&2016, Al-Agouza Hospital.
Conclusion: our findings suggest that serum FGF-23 level in hemodialysis patients is significantly correlated with serum hemoglobin level. Serum FGF-23 is significantly higher in diabetic patients than non-diabetics. PTH levels is significantly higher in the hemodialysis patients especially non diabetics.
Recommendations: Fibroblast Growth factor-23 is related to anemia in hemodialysis patients, so more studies or studies conducted on large number of patients may help to find recent modalities to decrease FGF-23 thus help improving anemia in hemodialysis patients. Correction of serum FGF-23 level may help in correction of serum calcium and PTH. FGF-23 may be used in the follow up of diabetic nephropathy.